MedTrace Logo

Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients

NCT02942550 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2018-04-09

No results posted yet for this study

Summary

This study will examine the impact of the peripheral opioid antagonist methylnaltrexone on the onset of effect of ticagrelor in morphine treated patients with ST elevation myocardial infarction (STEMI). Half of the participants will receive methylnaltrexone, while the other half will receive placebo.

Conditions

  • STEMI
  • Morphine
  • Ticagrelor
  • Methylnaltrexone

Interventions

DRUG

Methylnaltrexone bromide (Relistor®).

DRUG

Sodium Chloride 9mg/mL

Sponsors & Collaborators

  • Karolinska University Hospital

    lead OTHER

Principal Investigators

  • Per Tornvall, MD, PhD · Karolinska Institutet

  • Ulf Jensen, MD, PhD · Karolinska Institutet

  • Nawzad Saleh, MD, PhD · Karolinska Institutet

  • Loghman Henareh, MD; PhD · Karolinska Institutet

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02942550 on ClinicalTrials.gov